Michael O’Rourke

Chief Executive Officer Re-Vana Therapeutics

Seminars

Wednesday 28th January 2026
The Sustained Release of Biologics, Large, & Small Molecules with Novel Photo Crosslinked Biodegradable Technologies
10:00 am
  • Transforming Anti-VEGF Delivery: How Re-Vana’s sustained-release technology could reduce injection frequency for patients with retinal diseases
  • Innovation at the Interface of Science & Patient Care: The science behind ReVana’s biodegradable implants and why it matters for the future of ophthalmology, including novel sustained release therapeutics 
  • Opportunities for Collaboration & Impact: Where Re-Vana is today and the potential paths forward, clinical development, partnerships, and commercial strategy
Michael O’Rourke, Chief Executive Officer, Re-Vana Therapeutics
View all Speakers
View Event Brochure